Publications by authors named "Amedeo Cefaliello"
Aims: Recently, precision medicine has drastically modified clinical paradigm for the clinical stratification of high-grade serous ovarian cancer (HGSOC) patients. International societies approved poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs) to treat platinum-sensitive defective HGSOC patients. Beyond , functional defects in homologous recombination repair (HRR) proteins laid the basis for genomic instability evaluation in HGSOC patients.
View Article and Find Full Text PDFImmunotherapy has revolutionized the treatment landscape for solid tumours. Here, we describe the case of a 69-year-old woman with advanced endometrial cancer (EC) who achieved prolonged disease control with immunotherapy. The patient was diagnosed with stage IIIC EC in February 2020 and was treated with carboplatin and paclitaxel, followed by radiotherapy.
View Article and Find Full Text PDFArticle Synopsis
- This study examines the effectiveness of Poly ADP-ribose polymerase inhibitors (PARPi) in patients with BRCA mutations undergoing treatment for advanced ovarian cancer.
- A retrospective analysis of 79 patients revealed no significant differences in progression-free survival (PFS) based on specific BRCA domain defects or mutation types.
- The findings suggest that the success of PARPi maintenance treatment is largely independent of the BRCA defects or mutations.
Unlabelled: Breast cancer is the most frequently diagnosed cancer in women worldwide. Actually CDK4/6 inhibitor Ribociclib is approved for the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer, but comorbidities like infectious or cardiovascular diseases may limit its use.
Case Report: A 45-year-old woman was diagnosed with metastatic breast cancer in September 2021; also, her hepatitis screening resulted positive for hepatitis B infection.
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies worldwide. Fortunately, recent advances in OC biology and the discovery of novel therapeutic targets have led to the development of novel therapeutic agents that may improve the outcome of OC patients. The glucocorticoid receptor (GR) is a ligand-dependent transcriptional factor known for its role in body stress reactions, energy homeostasis and immune regulation.
View Article and Find Full Text PDF